<!DOCTYPE html>
<!-- saved from url=(0076)https://us21.campaign-archive.com/?u=506ac9dc6e88b1ae3fedcece9&id=6357ab3f35 -->
<html xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:og="http://opengraph.org/schema/"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        
<meta property="og:title" content="bancroft ai - Karuna&#39;s NDA Submission, Soleno Riase, Bionix PTSD Data, Entyvio&#39;s Expeanded Indication">
<meta property="fb:page_id" content="43929265776">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
<meta name="referrer" content="origin">        
<!--[if gte mso 15]>
<xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
<o:PixelsPerInch>96</o:PixelsPerInch>
</o:OfficeDocumentSettings>
</xml>
<![endif]-->

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1">

<link rel="icon" type="image/png" href="favicon.png"/>    
<title>bancroft ai - New Pompe Approval, AbbVie’s Phase 3 Data, Madrigal and Synlogic and Many More Raise Money</title>
<link rel="stylesheet" href="./9292023_files/css"><style>          img{-ms-interpolation-mode:bicubic;} 
          table, td{mso-table-lspace:0pt; mso-table-rspace:0pt;} 
          .mceStandardButton, .mceStandardButton td, .mceStandardButton td a{mso-hide:all !important;} 
          p, a, li, td, blockquote{mso-line-height-rule:exactly;} 
          p, a, li, td, body, table, blockquote{-ms-text-size-adjust:100%; -webkit-text-size-adjust:100%;} 
          @media only screen and (max-width: 480px){
            body, table, td, p, a, li, blockquote{-webkit-text-size-adjust:none !important;} 
          }
          .mcnPreviewText{display: none !important;} 
          .bodyCell{margin:0 auto; padding:0; width:100%;}
          .ExternalClass, .ExternalClass p, .ExternalClass td, .ExternalClass div, .ExternalClass span, .ExternalClass font{line-height:100%;} 
          .ReadMsgBody{width:100%;} .ExternalClass{width:100%;} 
          a[x-apple-data-detectors]{color:inherit !important; text-decoration:none !important; font-size:inherit !important; font-family:inherit !important; font-weight:inherit !important; line-height:inherit !important;} 
            body{height:100%; margin:0; padding:0; width:100%; background: #ffffff;}
            p{margin:0; padding:0;} 
            table{border-collapse:collapse;} 
            td, p, a{word-break:break-word;} 
            h1, h2, h3, h4, h5, h6{display:block; margin:0; padding:0;} 
            img, a img{border:0; height:auto; outline:none; text-decoration:none;} 
            a[href^="tel"], a[href^="sms"]{color:inherit; cursor:default; text-decoration:none;} 
            li p {margin: 0 !important;}
            .ProseMirror a {
                pointer-events: none;
            }
            @media only screen and (max-width: 480px){
                body{width:100% !important; min-width:100% !important; } 
                body.mobile-native {
                    -webkit-user-select: none; user-select: none; transition: transform 0.2s ease-in; transform-origin: top center;
                }
                body.mobile-native.selection-allowed a, body.mobile-native.selection-allowed .ProseMirror {
                    user-select: auto;
                    -webkit-user-select: auto;
                }
                colgroup{display: none;}
                img{height: auto !important;}
                .mceWidthContainer{max-width: 660px !important;}
                .mceColumn{display: block !important; width: 100% !important;}
                .mceColumn-forceSpan{display: table-cell !important; width: auto !important;}
                .mceBlockContainer{padding-right:16px !important; padding-left:16px !important;} 
                .mceBlockContainerE2E{padding-right:0px; padding-left:0px;} 
                .mceSpacing-24{padding-right:16px !important; padding-left:16px !important;}
                .mceFooterSection .mceText, .mceFooterSection .mceText p{font-size: 16px !important; line-height: 140% !important;}
                .mceText, .mceText p{font-size: 16px !important; line-height: 140% !important;}
                h1{font-size: 30px !important; line-height: 120% !important;}
                h2{font-size: 26px !important; line-height: 120% !important;}
                h3{font-size: 20px !important; line-height: 125% !important;}
                h4{font-size: 18px !important; line-height: 125% !important;}
            }
            @media only screen and (max-width: 640px){
                .mceClusterLayout td{padding: 4px !important;} 
            }
            div[contenteditable="true"] {outline: 0;}
            .ProseMirror .empty-node, .ProseMirror:empty {position: relative;}
            .ProseMirror .empty-node::before, .ProseMirror:empty::before {
                position: absolute;
                left: 0;
                right: 0;
                color: rgba(0,0,0,0.2);
                cursor: text;
            }
            .ProseMirror .empty-node:hover::before, .ProseMirror:empty:hover::before {
                color: rgba(0,0,0,0.3);
            }
            .ProseMirror h1.empty-node:only-child::before,
            .ProseMirror h2.empty-node:only-child::before,
            .ProseMirror h3.empty-node:only-child::before,
            .ProseMirror h4.empty-node:only-child::before {
                content: 'Heading';
            }
            .ProseMirror p.empty-node:only-child::before, .ProseMirror:empty::before {
                content: 'Start typing...';
            }
            a .ProseMirror p.empty-node::before, a .ProseMirror:empty::before {
                content: '';
            }
            .mceText, .ProseMirror {
                white-space: pre-wrap;
            }
body, #bodyTable { background-color: rgb(244, 244, 239); }.mceText, .mceLabel { font-family: Roboto, "Helvetica Neue", Helvetica, Arial, sans-serif; }.mceText, .mceLabel { color: rgb(30, 27, 21); }.mceText h1 { margin-bottom: 0px; }.mceText p { margin-bottom: 0px; }.mceText ul { margin-bottom: 0px; }.mceText label { margin-bottom: 0px; }.mceText input { margin-bottom: 0px; }.mceSpacing-24 .mceInput + .mceErrorMessage { margin-top: -12px; }.mceText h1 { margin-bottom: 0px; }.mceText p { margin-bottom: 0px; }.mceText ul { margin-bottom: 0px; }.mceText label { margin-bottom: 0px; }.mceText input { margin-bottom: 0px; }.mceSpacing-12 .mceInput + .mceErrorMessage { margin-top: -6px; }.mceText h1 { margin-bottom: 0px; }.mceText p { margin-bottom: 0px; }.mceText ul { margin-bottom: 0px; }.mceText label { margin-bottom: 0px; }.mceText input { margin-bottom: 0px; }.mceSpacing-48 .mceInput + .mceErrorMessage { margin-top: -24px; }.mceInput { background-color: transparent; border: 2px solid rgb(208, 208, 208); width: 60%; color: rgb(77, 77, 77); display: block; }.mceInput[type="radio"], .mceInput[type="checkbox"] { float: left; margin-right: 12px; display: inline; width: auto !important; }.mceLabel > .mceInput { margin-bottom: 0px; margin-top: 2px; }.mceLabel { display: block; }.mceText p { color: rgb(30, 27, 21); font-family: Roboto, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 18px; font-weight: normal; line-height: 1.5; text-align: left; letter-spacing: 0px; direction: ltr; }.mceText h1 { color: rgb(30, 27, 21); font-family: "Helvetica Neue", Helvetica, Arial, Verdana, sans-serif; font-size: 31px; font-weight: bold; line-height: 1.5; text-align: center; letter-spacing: 0px; direction: ltr; }.mceText a { color: rgb(0, 0, 0); font-style: normal; font-weight: normal; text-decoration: underline; direction: ltr; }
@media only screen and (max-width: 480px) {
            .mceText p { font-size: 16px !important; line-height: 1.5 !important; }
          }
@media only screen and (max-width: 480px) {
            .mceText h1 { font-size: 31px !important; line-height: 1.5 !important; }
          }
@media only screen and (max-width: 480px) {
            .mceBlockContainer { padding-left: 16px !important; padding-right: 16px !important; }
          }
#dataBlockId-9 p, #dataBlockId-9 h1, #dataBlockId-9 h2, #dataBlockId-9 h3, #dataBlockId-9 h4, #dataBlockId-9 ul { text-align: center; }
@media only screen and (max-width: 480px) {
        .mobileClass-4 {padding-left: 12 !important;padding-top: 0 !important;padding-right: 12 !important;}
      }</style>                 <link rel="stylesheet" href="./9292023_files/archivebar-desktop.css" mc:nocompile="">  
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("True"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA",function(){function e(){if(!r){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,o.appendChild(e),r=!0}}function t(e){r=!0;var n,t,a,i,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(o,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",i=(a.frameElement||a).style,i.width=0,i.height=0,i.border=0,i.display="none",o.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void 0;",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=14,window.BOOMR.url=n+"QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA";var i=document.currentScript||document.getElementsByTagName("script")[0],o=i.parentNode,r=!1,d=document.createElement("link");if(d.relList&&"function"==typeof d.relList.supports&&d.relList.supports("preload")&&"as"in d)window.BOOMR.snippetMethod="p",d.href=window.BOOMR.url,d.rel="preload",d.as="script",d.addEventListener("load",e),d.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!r)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),o.appendChild(d);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="",a="jj6l2aqxaefmkziw2wjq-f-5d864aeff-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"36","ak.cp":"641026","ak.ai":parseInt("761902",10),"ak.ol":"0","ak.cr":45,"ak.ipv":4,"ak.proto":"h2","ak.rid":"21e66a6e","ak.r":41488,"ak.a2":n,"ak.m":"x","ak.n":"essl","ak.bpcip":"74.124.189.0","ak.cport":55253,"ak.gh":"23.220.107.216","ak.quicv":"","ak.tlsv":"tls1.3","ak.0rtt":"","ak.csrc":"-","ak.acc":"","ak.t":"1695995283","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==JLAU/15eOlLMXHZyCVHubUbFvnbDurSK8cbzWGx5CL5fAnn0iYE5gZuJXW1Cdoq4KICzHDg9WEx/Ec7XsXRPuHgDJvMmuJu1jyL8IhwerBtkvZxBeROmrFvFDGU+2Xg4P+Nt1NuR+lCrqO1diBCYBuJs3O8QLrow8QtOqxkQnmKKZyz1wh+2Bcq7XaUFAYuTzXzGyfdjkFnvrnlfcVDmWUYqV4R445UshoQ63iTToD7Y+1/ePc8Rev9o4NiPem/YGxi1lSG4nmzSO2bvLFin1164x0Y4zc+H+FFJ5RtfqQhBLRLKVrrMCVOZnnfH/KRvdl2gQLBA6IrTpe6zKDBUuvIKAlxM/OzPZiKgxsVOVepAh/IWMvkcLfF1ha6lJrYmOceb2s+kN5txe+7rJkdEJZZqrjrImAW7QmYRoNjIgzU=","ak.pv":"84","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="./9292023_files/QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA" rel="preload" as="script"><script id="boomr-scr-as" src="./9292023_files/QAT5G-9HZLF-7EDMX-YMVCJ-QZJDA" async=""></script></head> <body id="archivebody"> <div id="awesomewrap"> <div id="awesomeshare"> <div id="zclipwrap"> <div class="copy-container"> <label for="clipboardSource">Campaign URL</label> <span id="copyURL"> <input id="clipboardSource" name="shorturl" style="margin-top:6px;" type="text" value="https://us21.campaign-archive.com/?u=506ac9dc6e88b1ae3fedcece9&amp;id=6357ab3f35" class="av-text"> <a id="copyToClipboard" href="javascript:;">Copy</a> </span> </div>  </div> <ul id="awesomesocial"> <li class="twt"> <div> <a title="Share on Twitter" target="_blank" href="https://twitter.com/share?url=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35" rel="noopener noreferrer">Twitter <b>0 <i>tweets</i></b></a> </div>  </li> </ul> </div> <ul id="awesomebar"> <li> <a href="http://eepurl.com/isHCgI" title="Subscribe to List" target="_blank" rel="noopener noreferrer">Subscribe</a> </li>  <li class="float-r more"><a href="javascript:;" data-to-toggle="#translate"></a> <ul id="translate"> <li> <a rel="nofollow" title="English" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|en&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">English</a> </li><li> <a rel="nofollow" title="العربية" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ar&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">العربية</a> </li><li> <a rel="nofollow" title="Afrikaans" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|af&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Afrikaans</a> </li><li> <a rel="nofollow" title="беларуская мова" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|be&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">беларуская мова</a> </li><li> <a rel="nofollow" title="български" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|bg&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">български</a> </li><li> <a rel="nofollow" title="català" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ca&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">català</a> </li><li> <a rel="nofollow" title="中文（简体）" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|zh-CN&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">中文（简体）</a> </li><li> <a rel="nofollow" title="中文（繁體）" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|zh-TW&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">中文（繁體）</a> </li><li> <a rel="nofollow" title="Hrvatski" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|hr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Hrvatski</a> </li><li> <a rel="nofollow" title="Česky" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|cs&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Česky</a> </li><li> <a rel="nofollow" title="Dansk" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|da&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Dansk</a> </li><li> <a rel="nofollow" title="eesti&amp;nbsp;keel" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|et&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">eesti&nbsp;keel</a> </li><li> <a rel="nofollow" title="Nederlands" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|nl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Nederlands</a> </li><li> <a rel="nofollow" title="Suomi" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|fi&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Suomi</a> </li><li> <a rel="nofollow" title="Fran&amp;ccedil;ais" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|fr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Français</a> </li><li> <a rel="nofollow" title="Deutsch" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|de&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Deutsch</a> </li><li> <a rel="nofollow" title="&amp;Epsilon;&amp;lambda;&amp;lambda;&amp;eta;&amp;nu;&amp;iota;&amp;kappa;ή" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|el&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Ελληνική</a> </li><li> <a rel="nofollow" title="हिन्दी" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|hi&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">हिन्दी</a> </li><li> <a rel="nofollow" title="Magyar" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|hu&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Magyar</a> </li><li> <a rel="nofollow" title="Gaeilge" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ga&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Gaeilge</a> </li><li> <a rel="nofollow" title="Indonesia" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|id&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Indonesia</a> </li><li> <a rel="nofollow" title="íslenska" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|is&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">íslenska</a> </li><li> <a rel="nofollow" title="Italiano" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|it&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Italiano</a> </li><li> <a rel="nofollow" title="日本語" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ja&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">日本語</a> </li><li> <a rel="nofollow" title="ភាសាខ្មែរ" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|km&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">ភាសាខ្មែរ</a> </li><li> <a rel="nofollow" title="한국어" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ko&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">한국어</a> </li><li> <a rel="nofollow" title="македонски&amp;nbsp;јазик" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|mk&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">македонски&nbsp;јазик</a> </li><li> <a rel="nofollow" title="بهاس ملايو" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ms&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">بهاس ملايو</a> </li><li> <a rel="nofollow" title="Malti" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|mt&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Malti</a> </li><li> <a rel="nofollow" title="Norsk" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|no&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Norsk</a> </li><li> <a rel="nofollow" title="Polski" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|pl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Polski</a> </li><li> <a rel="nofollow" title="Portugu&amp;ecirc;s" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|pt&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Português</a> </li><li> <a rel="nofollow" title="Portugu&amp;ecirc;s&amp;nbsp;-&amp;nbsp;Portugal" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|pt-PT&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Português&nbsp;-&nbsp;Portugal</a> </li><li> <a rel="nofollow" title="Rom&amp;acirc;nă" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ro&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Română</a> </li><li> <a rel="nofollow" title="Русский" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ru&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Русский</a> </li><li> <a rel="nofollow" title="Espa&amp;ntilde;ol" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|es&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Español</a> </li><li> <a rel="nofollow" title="Kiswahili" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sw&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Kiswahili</a> </li><li> <a rel="nofollow" title="Svenska" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sv&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Svenska</a> </li><li> <a rel="nofollow" title="עברית" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|iw&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">עברית</a> </li><li> <a rel="nofollow" title="Lietuvių" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|lt&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Lietuvių</a> </li><li> <a rel="nofollow" title="latviešu" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|lv&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">latviešu</a> </li><li> <a rel="nofollow" title="slovenčina" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sk&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">slovenčina</a> </li><li> <a rel="nofollow" title="slovenščina" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">slovenščina</a> </li><li> <a rel="nofollow" title="српски" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|sr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">српски</a> </li><li> <a rel="nofollow" title="தமிழ்" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|ta&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">தமிழ்</a> </li><li> <a rel="nofollow" title="ภาษาไทย" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|th&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">ภาษาไทย</a> </li><li> <a rel="nofollow" title="Türkçe" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|tr&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Türkçe</a> </li><li> <a rel="nofollow" title="Filipino" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|tl&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Filipino</a> </li><li> <a rel="nofollow" title="украї́нська" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|uk&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">украї́нська</a> </li><li> <a rel="nofollow" title="Tiếng&amp;nbsp;Việt" href="http://translate.google.com/translate?hl=auto&amp;langpair=auto|vi&amp;u=https%3A%2F%2Fus21.campaign-archive.com%2F%3Fu%3D506ac9dc6e88b1ae3fedcece9%26id%3D6357ab3f35">Tiếng&nbsp;Việt</a> </li> </ul> </li> </ul> </div>
        
<!---->
<center>
<table border="0" cellpadding="0" cellspacing="0" height="100%" width="100%" id="bodyTable" style="background-color: rgb(244, 244, 239);">
<tbody><tr>
<td class="bodyCell" align="center" valign="top">
<table id="root" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody data-block-id="13" class="mceWrapper"><tr><td align="center" valign="top" class="mceWrapperOuter"><!--[if (gte mso 9)|(IE)]><table align="center" border="0" cellspacing="0" cellpadding="0" width="660" style="width:660px;"><tr><td><![endif]--><table border="0" cellpadding="0" cellspacing="0" width="100%" style="max-width:660px" role="presentation"><tbody><tr><td style="background-color:#f4f4ef;background-position:center;background-repeat:no-repeat;background-size:cover" class="mceWrapperInner" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="12"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td style="padding-top:0;padding-bottom:0" class="mceColumn" data-block-id="-8" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td style="padding-top:48px;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="1" class="mceText" id="dataBlockId-1" style="width:100%"><p class="last-child"> </p></div></td></tr><tr><td style="padding-top:12px;padding-bottom:5px;padding-right:48px;padding-left:48px" class="mceBlockContainer" align="center" valign="top"><img data-block-id="2" width="369" height="auto" style="width:369px;height:auto;max-width:100%;display:block" alt="" src="./9292023_files/45e2461b-dab9-a382-7d85-fbc2f179c6a4.png" role="presentation" class="imageDropZone"></td></tr><tr><td style="padding-top:0;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="16" class="mceText" id="dataBlockId-16" style="width:100%"><h1 style="text-align: center;" class="last-child"><span style="color:#80807f;"><span style="font-size: 20px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"><span style="font-weight:normal;">Pharma Intelligence for Industry Leaders</span></span></span></span></h1></div></td></tr><tr><td style="background-color:transparent;padding-top:20px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color:transparent" role="presentation" data-block-id="15"><tbody><tr><td style="min-width:100%;border-top:2px solid #7c7e73" valign="top"></td></tr></tbody></table></td></tr><tr><td style="background-color:transparent;padding-top:20px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="18" class="mceText" id="dataBlockId-18" style="width:100%"><h1 style="line-height: 1.25;" class="last-child">New Pompe Approval, AbbVie’s Phase 3 Data, Madrigal and Synlogic and Many More Raise Money</h1></div></td></tr><tr><td style="background-color:transparent;padding-top:20px;padding-bottom:20px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" style="background-color:transparent" role="presentation" data-block-id="19"><tbody><tr><td style="min-width:100%;border-top:2px solid #7c7e73" valign="top"></td></tr></tbody></table></td></tr><tr><td style="background-color:transparent;padding-top:12px;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" valign="top"><div data-block-id="3" class="mceText" id="dataBlockId-3" style="width:100%"><p style="line-height: 1.25; text-align: left;"><span style="text-decoration:underline;">Top News</span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Amicus</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (FOLD) has received FDA approval for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules, a two-component therapy for adults with late-onset Pompe disease (LOPD) who are not improving on their current enzyme replacement therapy (ERT) </span></span>(<a href="https://amicusrx.com/pi/pombiliti.pdf">prescribing information</a>)<span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">. LOPD is a rare, debilitating, and life-threatening disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). The approval was based on data from the Phase 3 pivotal study (PROPEL). The therapy will be launched immediately in the U.S. and has also been approved in the European Union and the United Kingdom. (</span></span><a href="https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-fda-approval-and-launch-new" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Synlogic</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (SYBX) announced publication of Synpheny-1 Phase 2 study of SYNB1618 (</span></span><a href="https://investor.synlogictx.com/news-releases/news-release-details/synlogic-announces-publication-synpheny-1-phase-2-study" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link to PR</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">; </span></span><a href="https://www.nature.com/articles/s42255-023-00897-6" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link to abstract</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">) and then announces pricing of their $21.0 Million offering. they plan to offer 7.394 million shares, each share and accompanying warrant is priced at $2.84, with the warrants having an exercise price of $3.408 per share. (</span></span><a href="https://investor.synlogictx.com/news-releases/news-release-details/synlogic-announces-pricing-210-million-underwritten-public" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p style="line-height: 1.25; text-align: left;"><br></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">PTC Therapeutics</span></span></span></strong><span style="color:#1319fb;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">(PTCT) announced a strategic prioritization and associated workforce reduction, impacting approximately 25% of the organization. The move is part of an ongoing process to focus resources on high potential R&amp;D programs and global commercial infrastructure. The company also plans to submit a re-examination request for the CHMP opinion on Translarna, a Duchenne muscular dystrophy therapy. The workforce reduction is expected to result in a 20% reduction in annual operating expenses compared to 2023 guidance. (</span></span><a href="https://www.prnewswire.com/news-releases/ptc-announces-further-strategic-prioritization-and-associated-reduction-in-workforce-301942301.html" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p style="line-height: 1.25;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> <br></span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Teva </span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">(TEVA) announces changes to executive management team, stating that " Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business." (</span></span><a href="https://www.businesswire.com/news/home/20230928260229/en/" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p><br></p><p><strong><span style="color:#427de3;">Ionis</span></strong> (IONS) announced publishing of eplontersan Phase 3 data in JAMA. Here’s our summary: </p><ul><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">The Phase 3 NEURO-TTRansform study of eplontersen, a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), achieved its primary endpoint of halting disease progression and improving quality of life at 35-, 66-, and 85-week analyses. The primary endpoint was statistically significant, with an 82% reduction in serum transthyretin (TTR) concentration from baseline at 65 weeks compared to an 11% reduction in the external placebo group (p&lt;0.001).<br>Other significant findings include improvements in neuropathy impairment and quality of life, with 47% of treated patients showing improvements in neuropathy at 66 weeks compared to 17% in the external placebo group. Eplontersen also demonstrated a 5.5 point decrease in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) at 66 weeks, compared to a 14.2 point increase in the external placebo group (p&lt;0.001).<br>The control group in this study was an external placebo group. Eplontersen also showed statistically significant improvements in all secondary endpoints through 66 weeks and maintained a favorable safety and tolerability profile.<br>Based on these results, Ionis Pharmaceuticals and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of ATTRv-PN in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration (FDA) granted a PDUFA action date of Dec. 22, 2023.</span></span></p><p><br></p></li></ul><p><br></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Elicio Therapeutics</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (ELTX) Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancers. (</span></span><a href="https://ir.elicio.com/news-releases/news-release-details/elicio-therapeutics-presents-updated-preliminary-data-including" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><ul><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">The Phase 1 trial of Elicio Therapeutics' ELI-002 2P, a therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRAS, achieved its primary endpoint of safety and recommended Phase 2 dose. The trial demonstrated a statistically significant correlation between T cell response and clinical efficacy, with patients showing greater than median T cell response not reaching median Relapse-Free Survival (RFS) compared to a median RFS of 3.91 months for patients with less than median T cell response.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">The trial also found an 86% reduction in risk of progression or death in patients with large T cell responses induced by ELI-002 2P. The control group for this study was treated with subcutaneous ELI-002 2P vaccine monotherapy.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Other significant findings include tumor biomarker response in 77% of patients, with clearance in 27%. No safety concerns were identified, and there were no dose limiting toxicities and no ≥ Grade 3 treatment related adverse events.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Based on these results, Elicio plans to initiate a randomized Phase 2 study in early 2024 for ELI-002 7P, a formulation designed to provide immune response coverage against seven of the most common KRAS mutations.</span></span></p></li></ul><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> <br></span></span><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Gamida Cell</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (GMDA) announced that the ‘first patient receives Gamida Cell's Omisirge™ (omidubicel-onlv)’. The company notes: "Omisirge is the only allogeneic stem cell therapy approved by the U.S. Food and Drug Administration (FDA) on the basis of a global randomized Phase 3 trial. Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress". (</span></span><a href="https://investors.gamida-cell.com/news-events/press-releases/news-release-details/first-patient-receives-gamida-cells-omisirgetm" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;">Takeda</span></strong> (TAK) announced that the ‘U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis’. From the press release: "ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy". (<a href="https://www.businesswire.com/news/home/20230927729603/en/" target="_blank">link</a>)</p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25;"><span style="text-decoration:underline;">Post-market Yesterday</span></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;">MEI Pharma </span></strong>(MEIP) has issued a statement in response to a consent solicitation initiated by Anson Advisors Inc. and Cable Car Capital LLC. The company's board and management team are focused on advancing their two programs, voruciclib and ME-344, which are on the verge of reporting clinical data that could support value creation opportunities for all stockholders. MEI Pharma accuses Anson and Cable Car of wanting the company's cash regardless of the opportunity cost to MEI's development programs and other stockholders. The company warns that if Anson and Cable Car are successful in their consent solicitation and upcoming proxy fight, it would disrupt the governance function of MEI and hinder the company's ability to create value from the expected upcoming data readouts from both programs. (<a href="https://www.meipharma.com/press-releases/mei-pharma-issues-statement-regarding-anson-and-cable-cars-opportunistic-actions" target="_blank">link</a>)</p><p><br></p><p><strong><span style="color:#427de3;">Verastem </span></strong>(VSTM) presents avutometinib and defactinib combination program updates at the 5th Annual RAS-Targeted Drug Development Summit. Here’s our summary of the data:</p><ul><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">The FRAME study achieved its primary endpoint, showing an overall response rate (ORR) of 42% in patients with low-grade serous ovarian cancer (LGSOC). The ORR was statistically significant, with a 58% ORR in patients with KRAS mutant LGSOC and a 33% ORR in patients with KRAS wild-type LGSOC. The median duration of response was 26.9 months, and the median progression-free survival (PFS) was 20.0 months.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">The study evaluated the combination of avutometinib and defactinib in patients with advanced solid tumors, including recurrent LGSOC. The control group was treated with standard chemotherapy or hormonal therapy.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Other significant findings include a tolerable safety profile and a high rate of objective responses in the recurrent LGSOC cohort. As of July 2023, 19% of patients were still on study treatment with a minimum follow-up of 17 months.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Based on these results, Verastem Oncology plans to continue the development of avutometinib and defactinib for the treatment of LGSOC. The U.S. Food and Drug Administration has granted Breakthrough Therapy designation for this combination treatment.</span></span></p></li></ul><p><br></p><p><strong><span style="color:#427de3;">Quice Therapeutics</span></strong> (QNCX) announced U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia. (<a href="https://ir.quincetx.com/news-releases/news-release-details/us-fda-partial-clinical-hold-lifted-ind-erydels-lead-phase-3" target="_blank">link</a>)</p><p><br></p><p><strong><span style="color:#427de3;">Better Therapeutics</span> </strong>Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes. (<a href="https://www.businesswire.com/news/home/20230928483146/en/" target="_blank">link</a>)</p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25; text-align: left;"><span style="color:#1e1b15;"><span style="text-decoration:underline;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Pre-market Today</span></span></span></span></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;">Regeneron’s </span></strong>(REGN) odronextamab granted Priority Review by FDA for treatment of relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). (<a href="https://investor.regeneron.com/news-releases/news-release-details/odronextamab-bla-treatment-relapsedrefractory-follicular" target="_blank">link</a>)</p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;">SeaStar Medical</span></strong> (ICU) has been granted Breakthrough Designation for its “selective cytopheretic device for cardiorenal syndrome”. (<a href="https://investors.seastarmedical.com/news/news-details/2023/FDA-Grants-Breakthrough-Device-Designation-to-SeaStar-Medicals-Selective-Cytopheretic-Device-for-Cardiorenal-Syndrome/default.aspx" target="_blank">link</a>)</p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">AbbVie </span></span></span></strong><span style="color:#1e1b15;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">(ABBV) has received Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers. Take a look at our summary over on linkedin (</span></span></span><a href="https://www.linkedin.com/feed/update/urn:li:activity:7113488552235057152" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="color:#1e1b15;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">).</span></span></span></p><p style="line-height: 1.25;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">NANOBIOTIX</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (CALT) announces presentation of first data From Phase 1 study evaluating NBTXR3 for patients With locally advanced pancreatic cancer. Here’s our summary of the data:</span></span></p><ul><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">The Phase 1 clinical trial evaluating NBTXR3 for patients with locally advanced pancreatic cancer achieved its primary endpoint, establishing the recommended phase 2 dose (RP2D) at 42% of gross tumor volume. The trial demonstrated a local disease control rate of 92.3% (12 out of 13 patients) and a median overall survival of 21 months in evaluable patients. The trial's primary endpoint was to determine the RP2D, which was achieved without any injection complications.<br>The trial also found that NBTXR3, when activated by radiotherapy, was feasible and had a tolerable safety profile. One patient experienced a dose-limiting toxicity related to radiotherapy, which was a Grade 3 elevated liver function.<br>The control group for this study consisted of patients who had previously received a 4-month course of chemotherapy and showed no radiographic evidence of metastases at screening.<br>These results suggest that NBTXR3, when activated by radiotherapy, has promising anti-tumor efficacy and supports further development in pancreatic cancer. The expansion part of the study remains ongoing.</span></span></p></li></ul><p style="line-height: 1.25; text-align: left;"><br></p><p style="line-height: 1.25; text-align: left;"><span style="text-decoration:underline;">Raising Money</span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Portage Biotech</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (PRTG) announced a $6.0 million offering of 3.158 million shares at a price of $1.90 per share. (</span></span><a href="https://ir.portagebiotech.com/news-releases/news-release-details/portage-biotech-announces-60-million-registered-direct-offering" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> &nbsp;</span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Lexaria</span></span></span></strong><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> (LEXXW) announced pricing of $1.6 Million offering of 1.618 million shares at a price of $0.97 per share. (</span></span><a href="https://ir.lexariabioscience.com/news-events/press-releases/detail/224/lexaria-announces-pricing-of-1-6-million-registered-direct" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">)</span></span></p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;">Hepion Pharmaceuticals</span></strong> (HEPA) announces $5.0 million offering of 980,393 shares priced at-the-market which is $5.10 per share. Concurrently, Hepion will issue Series A and Series B Warrants to the investor, allowing them to purchase up to an aggregate of 980,393 shares of common stock. The warrants have an exercise price of $4.85 per share and will expire in five years and one and a half years, respectively. The closing of the offering and private placement is expected to occur on October 3, 2023. (<a href="https://hepionpharma.com/news/hepion-pharmaceuticals-announces-5-0-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules/" target="_blank">link</a>) </p><p style="line-height: 1.25;"><br></p><p style="line-height: 1.25;"><strong><span style="color:#427de3;">Capricor Therapeutics </span></strong><span style="color:#1e1b15;">(CAPR), after announcing they had a good Type B meeting with FDA (</span><a href="https://www.capricor.com/investors/news-events/press-releases/detail/261/capricor-therapeutics-announces-positive-type-b-meeting" target="_blank">link to that PR</a><span style="color:#1e1b15;">), announced a $23 million offering of 4.936 million shares. Each share comes with a warrant to purchase another share at $5.70, excercisable six months after issuance and expiring seven years from the date of issuance. Yesterdays closing price was $5.82.The combined offering price is $4.66 per share. Pre-market the stock is down -25%. (</span><a href="https://www.capricor.com/investors/news-events/press-releases/detail/262/capricor-therapeutics-announces-23-million-registered" target="_blank">link</a><span style="color:#1e1b15;">)</span></p><p style="line-height: 1.25; text-align: left;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> &nbsp;</span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Structure Therapeutics</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">(GPCR), after announcing what they called "positive" Phase 1b results (</span></span><a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-positive-results-phase-1b" target="_blank"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">link to that PR</span></span></a><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">), announced a $300 million private placement. They are selling 21.617 million shares and 2.402 million non-voting shares, the company notes that this is the equivalent aggregate of 8.006 million ADSs at $12.49 per share based on a closing price of $37.46 per ADS yesterday.</span></span> (<a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-300-million-private-placement" target="_blank">link</a>)</p><p><br></p><p><strong><span style="color:#427de3;">Madrigal Pharmaceuticals</span></strong> (MDGL) announced a $500 million offering. They plan to offer 1.248 million shares at $151.69 per share, and pre-funded warrants to purchase over 2.048 million shares at $151.6899 per share. The underwriters have a 30-day option to purchase up to an additional 494,429 shares. (<a href="https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-pricing-500-million-public" target="_blank">link</a>)</p><p><br></p><p><strong><span style="color:#427de3;">Tonix Pharmaceuticals</span></strong> (TNXP) plans to offer9 million shares, along with Series A and Series B warrants, at a price of $0.50.&nbsp;(<a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1425/tonix-pharmaceuticals-announces-pricing-of-4-5-million" target="_blank">link</a>)</p><p><br></p><p><strong><span style="color:#427de3;">Vaccinex </span></strong>(VCNX) announced a$9.6 million offering, the plan to offer 9.6 million shares at $1.00 per share. (<a href="https://ir.vaccinex.com/news-releases/news-release-details/vaccinex-announces-pricing-96-million-public-offering" target="_blank">link</a>)</p><p><br></p><p><strong><span style="color:#427de3;">TransCode Therapeutics</span></strong> (RNAZ) announced closing of $5.8 million offering of 16.863 million shares or pre-funded warrants, at a price of $0.51 per share. (<a href="https://ir.transcodetherapeutics.com/news-releases/news-release-details/transcode-therapeutics-announces-closing-85-million-public" target="_blank">link</a>)</p><p><br></p><p><span style="text-decoration:underline;">Financial Reports</span></p><p><strong><span style="color:#427de3;">Akari </span></strong>(AKTX) reports 1H 2023 financial results. Here is our summary:</p><ul><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Financial Position:</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- As of June 30, 2023, the company had cash of approximately $7.2 million.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Research and development expenses were approximately $3.3 million for the six months ended June 30, 2023, compared to approximately $5.0 million for the same period in 2022.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- General and administrative expenses were approximately $6.0 million for the six months ended June 30, 2023, compared to approximately $6.1 million for the same period in 2022.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Total other income was approximately $6.2 million for the six months ended June 30, 2023, compared to approximately $0.2 million for the same period in 2022.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Net loss was approximately $3.0 million for the six months ended June 30, 2023, compared to net loss of approximately $10.9 million for the same period in 2022.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Program Updates:</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Akari's priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA).</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Akari was granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Akari is also moving forward into a registrational Phase 3 double-blind placebo-controlled clinical trial of nomacopan in adult HSCT-TMA with enrollment expected to begin in 2024 (subject to funding).</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Akari completed evaluation of long-acting PAS-nomacopan candidates and based on extensive pre-clinical work selected a single drug candidate to move forward into clinical trials for treatment of GA.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Corporate Updates:</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- The company established a Boston U.S. headquarters office to support expanding operations and the start of registrational Phase 3 clinical trials.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Strengthened capabilities with appointment of Beth-Anne Lang, an experienced executive with a long track record of successful regulatory approvals, as Senior Vice President, Regulatory Affairs, and industry veterans Wa'el Hashad as independent director and Wendy DiCicco as interim CFO.</span></span></p></li></ul><p style="line-height: 1.25;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Apollomics</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">(APLM) reports first half 2023 financial results and provides corporate update. Here’s our summary: </span></span></p><ul><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Financial Position:<br>- Cash, cash equivalents, and investments as of June 30, 2023, were approximately $52.6 million, compared with $58.9 million as of December 31,2022.<br>- The company raised $23.7 million in a private placement in public equity(PIPE) financing in March 2023.<br>- The company believes its cash position is sufficient to fund planned operations into the second half of 2024.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Revenues and Expenses:<br>- Research and development (R&amp;D) expenses were $16.5 million in thefirst six months of 2023, compared to $18.0 million in the same period of2022.<br>- General and administrative (G&amp;A) expenses were $9.7 million in thefirst six months of 2023, compared to $5.1 million in the same period of2022.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Net Loss:<br>- The net loss for the first six months of 2023 was $(150.7) million, or$(2.55) per diluted share, compared with a net loss for the first six monthsof 2022 of $(3.4) million, or $(0.68) per diluted share.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Program Updates:<br>- The company expects results from its ongoing global Phase 2 multi-cohort clinical trial in NSCLC and other solid tumors with cMet dysregulations in the second half of 2023.<br>- The vebreltinib NDA for treatment of NSCLC with MET exon14 skipping mutation was submitted by Beijing Pearl to the China National Medical Products Administration (NMPA) in September 2022, with an NDA review decision anticipated in 2023.<br>- The company expects to complete patient recruitment of its Phase 3bridging clinical study for uproleselan for the treatment ofrelapsed/refractory (r/r) AML in China in 2023.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Corporate Updates:<br>- On March 29, 2023, Apollomics completed its business combination with Maxpro Capital Acquisition Corp. Apollomics' Class A ordinary shares and public warrants began trading on March 30, 2023, on the Nasdaq Capital Market under the symbols "APLM" and "APLMW", respectively.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">bancroft ai insights: Considering the net loss of $150.7 million for the first half of 2023, and assuming a consistent burn rate, the company has approximately 4 months of operation left with its current net cash of $52.6million. Remember, this is only considering the context of this single press release, and does not take into account the overall financial state of the company.</span></span></p><p><br></p></li></ul><p style="line-height: 1.25; text-align: left;"><br></p><p style="line-height: 1.25; text-align: left;"><strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">Inventiva</span></span></span></strong><span style="color:#427de3;"><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif"> </span></span></span><span style="font-size: 18px"><span style="font-family: &#39;Roboto&#39;, &#39;Helvetica Neue&#39;, Helvetica, Arial, sans-serif">(IVA) reports its 2023 first-half financial results and provides a corporate update. Here’s our summary:</span></span></p><ul class="last-child"><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Financial Position:</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million, and long-term deposit at €9.3 million as of June 30, 2023.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Revenues amounted to €1.9 million for the first half of 2023.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- In August 2023, Inventiva received a financing of approximately €35.7 million from new and existing investors.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- In September 2023, Inventiva announced an exclusive licensing agreement with Hepalys Pharma, Inc., to develop and commercialize lanifibranor for the treatment of NASH and potentially other metabolic diseases in Japan and South Korea. Inventiva will receive a $10 million upfront payment and is eligible to receive up to $231 million in milestone payments.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Guidance:</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- With the financial raise of €35.7 million, the expected upfront payment of $10 million from Hepalys Pharma, Inc. and milestone payment from CTTQ, Inventiva will meet the financial condition for the disbursement of the second tranche of €25 million of the European Investment Bank ("EIB"), which is expected to extend Inventiva's estimated cash runway until the beginning of the third quarter of 2024.</span></span></p></li><li style="color: #726b5c; line-height: 1.25;"><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">Program Updates:</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Implementation of a new ATM program replacing the existing program.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- In July 2023, Inventiva announced positive topline results of the Phase II clinical trial conducted by Dr. Kenneth Cusi, evaluating lanifibranor in patients with NAFLD and T2D, and confirming its favorable safety and tolerability profile.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- First visit of the last patient for NATiV3 is targeted by the end of the second half of 2023.</span></span></p><p style="line-height: 1.25;"><span style="color:#726b5c;"><span style="font-size: 16px">- Topline results of the LEGEND study with lanifibranor and empagliflozin in patients with NASH and T2D expected for the end of the first quarter of 2024.</span></span></p></li></ul></div></td></tr><tr><td style="padding-top:12px;padding-bottom:12px;padding-right:24px;padding-left:24px" class="mceBlockContainer" align="center" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" role="presentation" data-block-id="20"><tbody><tr class="mceStandardButton"><td style="background-color:#000000;border-radius:0;text-align:center" class="mceButton" valign="top"><a href="https://bancroft.ai/" target="_blank" style="background-color:#000000;border-radius:0;border:2px solid #000000;color:#ffffff;display:block;font-family:&#39;Helvetica Neue&#39;, Helvetica, Arial, Verdana, sans-serif;font-size:16px;font-weight:normal;font-style:normal;padding:16px 28px;text-decoration:none;min-width:30px;text-align:center;direction:ltr;letter-spacing:0px">subscribe at bancroft.ai</a></td></tr><tr>
<!--[if mso]>
<td align="center">
<v:roundrect xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:w="urn:schemas-microsoft-com:office:word"
href="https://bancroft.ai/"
style="v-text-anchor:middle; width:224.99px; height:54.22px;"
arcsize="0%"
strokecolor="#000000"
strokeweight="2px"
fillcolor="#000000">
<v:stroke dashstyle="solid"/>
<w:anchorlock />
<center style="
color: #ffffff;
display: block;
font-family: 'Helvetica Neue', Helvetica, Arial, Verdana, sans-serif;
font-size: 16;
font-style: normal;
font-weight: normal;
letter-spacing: 0px;
text-decoration: none;
text-align: center;
direction: ltr;"
>
subscribe at bancroft.ai
</center>
</v:roundrect>
</td>
<![endif]-->
</tr></tbody></table></td></tr><tr><td style="padding-top:12px;padding-bottom:12px;padding-right:0;padding-left:0" class="mceLayoutContainer" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="7"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="24" width="100%" role="presentation"><tbody><tr><td style="margin-bottom:24px" class="mceColumn" data-block-id="-7" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td align="center" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="" role="presentation" class="mceClusterLayout" data-block-id="-6"><tbody><tr><td style="padding-left:24px;padding-top:0;padding-right:24px" data-breakpoint="4" valign="top" class="mobileClass-4"><a href="https://linkedin.com/company/bancroft-ai/" style="display:block" target="_blank" data-block-id="-5"><img width="40" height="auto" style="border:0;width:40px;height:auto;max-width:100%;display:block" alt="LinkedIn icon" src="./9292023_files/linkedin-filled-dark-40.png" class=""></a></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr><tr><td style="padding-top:8px;padding-bottom:8px;padding-right:8px;padding-left:8px" class="mceLayoutContainer" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="11" id="section_7ab9ee1066b227d4bccb43d31ba3bcf5" class="mceFooterSection"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="12" width="100%" role="presentation"><tbody><tr><td style="padding-top:0;padding-bottom:0;margin-bottom:12px" class="mceColumn" data-block-id="-3" valign="top" colspan="12" width="100%"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"><tbody><tr><td style="padding-top:12px;padding-bottom:12px;padding-right:16px;padding-left:16px" class="mceBlockContainer" align="center" valign="top"><div data-block-id="9" class="mceText" id="dataBlockId-9" style="display:inline-block;width:100%"><p class="last-child"><em><span style="font-size: 12px">Copyright (C) 2023 bancroft ai. All rights reserved.</span></em><br></p></div></td></tr><tr><td class="mceLayoutContainer" align="center" valign="top"><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation" data-block-id="-2"><tbody><tr class="mceRow"><td style="background-position:center;background-repeat:no-repeat;background-size:cover" valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" role="presentation"></div></div></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><!--[if (gte mso 9)|(IE)]></td></tr></table><![endif]--></td></tr></tbody></table>
</td>
</tr>
</tbody></table>
</center>
    <script src="./9292023_files/jquery.min.js.download"></script><script type="text/javascript">
            $(document).ready(function() {
                document.getElementById("copyToClipboard").addEventListener("click", function () {
                    var input = document.getElementById("clipboardSource");
                    input.select();
                    var successful = document.execCommand("copy");
                    if (successful) {
                        alert('Copied "' + input.value + '" to your clipboard.');
                    } else {
                        throw new Error("Failed to copy text (verify caller was in the context of an event handler)");
                    }
                });

                $('li.more > a').click(function(){
                    var toToggle = $($(this).attr('data-to-toggle'));
                    if(toToggle.is(':visible')){
                        toToggle.slideUp('fast');
                        $(this).removeClass('is-active');
                        if ($('#awesomebar').find('.is-active').length < 1){
                            $('#awesomebar').removeClass('sub-active');
                        }
                    } else {
                        toToggle.slideDown('fast');
                        $(this).addClass('is-active');
                        $('#awesomebar').addClass('sub-active');
                    }
                    return false;
                });

            });
        </script> 
</body></html>